Alnylam pioneered RNA-interference drugs for rare and heart diseases.
Alnylam Pharmaceuticals, Inc. (ALNY) is expected to report earnings on Thursday, October 29, 2026, before the open. Estimated release time 08:05 ET. Consensus EPS estimate is $1.75.
| Report date | Quarter | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|---|
| 2026-07-30 | Jun 2026 qtr | $1.63 | $1.21 | — | $1.29B |
| 2026-04-30 | Mar 2026 qtr | $0.87 | $1.51 | — | $1.17B |
| 2026-02-12 | Dec 2025 qtr | $1.16 | $0.82 | — | $1.10B |
| 2025-10-30 | Sep 2025 qtr | $0.56 | $2.90 | — | $1.25B |
| 2025-07-31 | Jun 2025 qtr | $-0.54 | $-0.51 | — | $773.69M |
| 2025-05-01 | Mar 2025 qtr | $-0.89 | $-0.44 | — | $594.19M |
| 2025-01-13 | Dec 2024 qtr | $-0.62 | $-0.65 | — | $593.17M |
| 2024-10-31 | Sep 2024 qtr | $-0.92 | $-0.87 | — | $500.92M |